The discovery began, as many modern cancer biology investigations do, with proteomics. Rather than examining proteins one at a time, the researchers mapped the EphA2 interactome, the full constellation of proteins that physically associate with the EphA2 receptor, under conditions of progranulin stimulation. EphA2, or erythropoietin-producing hepatocellular carcinoma receptor A2, is a receptor tyrosine kinase that has long been implicated in cancer progression, but its behavior is unusual among kinase receptors: while it participates in normal developmental signaling, it is frequently overexpressed in aggressive tumors where its oncogenic function is driven less by classical kinase activity and more by its ability to recruit and organize signaling complexes. Progranulin, a secreted growth factor better known for its role in neurodegeneration, notably frontotemporal dementia, wound healing, and immune regulation, binds EphA2 and triggers downstream cascades. By comparing the composition of EphA2’s protein partners in the presence and absence of progranulin, the team uncovered a set of progranulin-dependent interactors, among them FAM120A, also known as Family with Sequence Similarity 120 Member A.

FAM120A is what biologists call a scaffold protein, a molecule that does not necessarily catalyze chemical reactions itself but instead serves as a physical platform upon which other signaling proteins assemble. This architectural role makes scaffold proteins powerful amplifiers and organizers of cellular communication, and disruptions in their function are increasingly recognized as contributors to malignancy. Using tissue microarrays and immunohistochemistry, the investigators demonstrated that FAM120A protein levels are elevated in bladder cancer tissues compared with normal tissue, suggesting that the protein is not merely a passive passenger but an active participant in the disease process.

To establish causality rather than mere correlation, the researchers turned to a battery of functional assays. They depleted FAM120A in bladder cancer cell lines using lentiviral shRNA approaches, a technique that uses viral vectors to deliver short hairpin RNA molecules capable of silencing a specific gene. The consequences were striking. Cells lacking FAM120A lost much of their clonogenic capacity, the ability to form colonies from single founder cells, a hallmark of cancer cell self-renewal. Wound healing assays, in which a scratch is made across a confluent cell monolayer and the rate of gap closure measured, showed dramatically impaired migratory capacity. Invasion through Matrigel, a synthetic basement membrane that mimics the extracellular matrix tumors must degrade to metastasize, was similarly crippled. Even three-dimensional spheroid formation, an in vitro model that captures aspects of tumor architecture more faithfully than flat cell culture, was compromised without FAM120A.

The team then extended these findings to anchorage-independent growth, assessed by soft agar assays, a classical test of malignant transformation in which cells must proliferate while suspended in semi-solid medium, something normal cells cannot do. FAM120A-depleted cells failed this test, and, critically, the loss of FAM120A also suppressed tumor formation in vivo using xenograft models, in which human cancer cells are implanted into immunocompromised mice. These animal experiments, performed under protocols approved by the Institutional Review Board of Thomas Jefferson University, provide the strongest evidence yet that FAM120A is not simply associated with aggressive bladder cancer but is functionally required for it.

Mechanistically, the study dissected how FAM120A exerts its oncogenic influence. Progranulin stimulation of bladder cancer cells is known to activate two major signaling highways: the AKT pathway, central to cell survival and growth, and the ERK1/2 pathway, a canonical mitogen-activated protein kinase cascade driving proliferation. Using western immunoblots, the researchers showed that FAM120A depletion blunted progranulin-evoked activation of both AKT and ERK1/2, placing the scaffold protein upstream of these critical signaling events. Co-immunoprecipitation experiments and proximity ligation assays, a technique that detects proteins located within roughly 40 nanometers of each other in intact cells, confirmed that the physical interaction between EphA2 and FAM120A is enhanced upon progranulin stimulation. Immunofluorescence microscopy further revealed colocalization of the two proteins within cells, painting a picture of a dynamically assembled signaling complex that assembles when progranulin arrives and drives the aggressive behavior of bladder cancer cells.

Perhaps the most mechanistically illuminating findings concern the cytoskeleton. For a cancer cell to migrate and invade, it must continuously remodel its actin cytoskeleton, the meshwork of F-actin filaments that provides mechanical force and shape. The team observed that progranulin stimulation triggers F-actin rearrangements in bladder cancer cells, and that this rearrangement is inhibited when FAM120A is depleted. Tracing the pathway further, they identified the small GTPase RhoA, a master regulator of actin dynamics and cell contractility, as a key mediator. Progranulin-induced activation of RhoA was abolished upon FAM120A depletion, and the researchers concluded that FAM120A operates through ERK1/2 and RhoA-dependent pathways to orchestrate the cytoskeletal changes that enable motility and invasion. This work builds on insights from experts in Rho protein biology, with the authors acknowledging discussions with Dr. Kenneth L. Van Golen of the University of Delaware.

The translational implications of these findings are twofold. First, FAM120A emerges as a candidate drug target. Because scaffold proteins occupy a nodal position in signaling networks, disrupting the EphA2-FAM120A interaction or destabilizing FAM120A itself could, in principle, simultaneously cripple multiple oncogenic outputs, from AKT-mediated survival to RhoA-driven invasion. Second, and more immediately achievable, FAM120A holds promise as a biomarker. Its upregulation in bladder cancer tissues suggests it could aid diagnosis, and the authors argue its expression patterns may carry prognostic value, potentially helping clinicians identify patients whose tumors are most likely to progress.

There is also an intriguing therapeutic synergy buried in the data. The researchers found that depleting FAM120A sensitized bladder cancer cells to cisplatin, a cornerstone chemotherapy drug used in the treatment of muscle-invasive and metastatic bladder cancer. Cisplatin kills cells primarily by cross-linking DNA, but resistance is a persistent clinical problem. The observation that removing a scaffold protein from a growth factor signaling axis can restore chemosensitivity hints that combinations of standard chemotherapy with agents targeting the progranulin/EphA2/FAM120A circuitry could one day improve outcomes, though such strategies remain firmly in the preclinical realm.

The collaborative nature of the study reflects the complexity of the problem. The work united researchers from Temple University in Philadelphia, Thomas Jefferson University’s Sidney Kimmel Cancer Center, the University of Siena, the University of Milano-Bicocca, the University of Naples Federico II, the University of Catania, the Mayo Clinic Alix School of Medicine, and the S.H.R.O. Italia Foundation, with funding from the Sbarro Health Research Organization and National Institutes of Health grants supporting Thomas Jefferson University’s Translational Core Facility. Corresponding author Andrea Morrione and colleagues, including co-author Antonio Giordano, director of the Sbarro Institute, and veteran extracellular matrix researcher Renato V. Iozzo, brought complementary expertise in growth factor signaling, proteomics, tumor biology, and translational oncology to bear on the question.

Important caveats remain. The study relies heavily on cell lines and xenograft models, which, while informative, do not fully recapitulate the heterogeneity of human bladder tumors or the microenvironment in which they grow. Whether FAM120A expression levels correlate with patient outcomes in large clinical cohorts, whether the protein can be safely and effectively targeted pharmacologically, and how its function intersects with established bladder cancer drivers such as FGFR3 alterations and immune checkpoint pathways are questions that will require substantial further research. The fact that progranulin also participates in neurodegenerative disease adds another layer of complexity, as any therapeutic strategy modulating progranulin signaling must carefully consider effects beyond the tumor.

Nevertheless, the identification of FAM120A as an oncogenic effector in the progranulin/EphA2 axis represents a meaningful advance in understanding how bladder cancer cells acquire their invasive, treatment-resistant phenotype. By converting a proteomic observation into a mechanistic model validated across molecular, cellular, and animal levels, the study provides the scientific community with both a new lens on an established signaling pathway and a concrete starting point for the development of diagnostic markers and therapeutic interventions. For a disease that kills nearly 18,000 Americans each year, that is progress worth noting.

Bladder cancer is not a single disease. Tumours that appear similar under a microscope can behave very differently, relapse at different rates and respond to entirely different treatments. Urothelial carcinoma, the most common form, is shaped by a complex mixture of genetic alterations, immune activity and changes in the tumour environment. Traditional clinical factors—such as tumour stage, grade, recurrence history and lymph-node involvement—remain essential, but they cannot fully explain this biological diversity. Biomarker testing offers a way to add that missing layer of information.

The group’s central message is that testing must be connected to a clinical decision. A biomarker is “actionable” when its result can influence treatment, surveillance or eligibility for a clinical trial. In bladder cancer, this may include alterations in the fibroblast growth factor receptor pathway, especially FGFR3, which can make some advanced tumours susceptible to FGFR-directed therapy. Other potentially relevant markers include programmed death-ligand 1, or PD-L1, which can help inform the use of immune checkpoint inhibitors in selected settings, as well as DNA repair defects, microsatellite instability and mismatch-repair deficiency, all of which may indicate an unusual sensitivity to immunotherapy.

The recommendations also highlight the importance of assessing HER2 biology, an area that has become increasingly relevant as antibody–drug conjugates and other targeted approaches expand. HER2 testing is not simply a matter of recording whether the protein is present or absent. Different laboratory methods can measure protein expression or gene amplification, and the result may depend on the assay, scoring system and quality of the tissue sample. Such technical details can determine whether a patient is correctly identified for a treatment opportunity, making standardized pathology procedures a critical part of precision oncology.

Timing is another major issue. Molecular information may be useful at diagnosis, before surgery, after recurrence or when metastatic disease develops, but the most informative sample can change as the cancer evolves. A tumour treated with chemotherapy, radiation, immunotherapy or targeted drugs may acquire new genetic features that were not present in the original biopsy. For this reason, the group supports a dynamic approach in which previously collected tissue is used when appropriate, while fresh tumour material—or, in selected circumstances, circulating tumour DNA from a blood sample—is considered when the disease changes.

This evolving biology creates a practical challenge for clinicians. A negative result from an old biopsy does not necessarily mean that a target is absent from a later tumour, just as a positive result may not guarantee that a treatment will work. Biomarkers are probabilities, not biological promises. Their interpretation must be combined with disease stage, previous therapies, organ function, patient preferences and the strength of evidence supporting a particular drug. The recommendations therefore emphasize multidisciplinary decision-making involving urologists, medical oncologists, pathologists, radiologists and molecular specialists.

The article also addresses the risk of fragmented testing. In many health systems, biomarker analysis is performed only after a patient has progressed through several lines of therapy, by which time an important treatment window may have passed. Tests may also be ordered inconsistently, interpreted using different criteria or delayed by limited access to specialized laboratories. The International Bladder Cancer Group calls for clearer testing pathways, validated assays and reporting systems that explain not only the molecular finding but also its clinical meaning, the available treatment options and the level of evidence behind them.

For patients, the shift could transform conversations about treatment. Instead of receiving a broadly defined diagnosis followed by a standard sequence of therapies, some individuals may be offered a strategy tailored to the molecular vulnerabilities of their cancer. A person whose tumour contains an actionable FGFR3 alteration, for example, may be considered for a pathway-specific drug, while another patient with immune-related biomarkers could be evaluated for checkpoint blockade. Those without an established target may be directed toward trials testing new combinations, novel antibody–drug conjugates or strategies designed to overcome resistance.

Yet precision medicine will not succeed through testing alone. The group stresses that biomarkers must be clinically validated, accessible and used equitably. Many promising molecular signals have not produced reliable benefits in large trials, and some tests remain too expensive or technically demanding for routine use. There is also a danger that unequal access to genomic profiling will widen existing differences in cancer outcomes. Integrating biomarkers into care therefore requires investment in laboratory quality, data interpretation, clinician education and reimbursement, alongside transparent communication with patients.

The wider significance of the recommendations reaches beyond bladder cancer. They represent a blueprint for moving from a one-size-fits-most model toward treatment decisions that reflect the biological identity of each tumour. As more targeted therapies and immunotherapies enter the clinic, the value of a biomarker will depend increasingly on how rapidly and accurately it can connect a patient to the right option. The International Bladder Cancer Group’s message is clear: molecular testing should not be an afterthought in bladder cancer care. It should become part of the clinical infrastructure that links diagnosis, treatment selection and the next generation of research.

Subject of Research: Bladder cancer biomarkers and their integration into clinical diagnosis, treatment selection, surveillance and precision oncology.

Article Title: Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

Article References: Hensley, P.J., Teoh, J.Y.C., Li, R. et al. Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01179-y

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01179-y

Keywords: bladder cancer, urothelial carcinoma, biomarkers, precision oncology, FGFR3, HER2, PD-L1, immunotherapy, targeted therapy, molecular testing, circulating tumour DNA, cancer care.

Bladder cancer remains one of the most prevalent malignancies worldwide, posing significant challenges due to its high recurrence rate and variable response to conventional treatments. Understanding the molecular players that drive its aggressive behavior is crucial for developing more effective therapeutic approaches. The recent findings highlight FBXL6 as a pivotal molecule that hijacks cellular processes to support cancer cell survival and proliferation, emphasizing the intricate biochemical networks that underlie tumor dynamics.

Ubiquitination, a post-translational modification process typically associated with protein degradation, plays many versatile roles within the cell. Unlike the more commonly studied K48-linked ubiquitination which tags proteins for destruction, K63-linked ubiquitination is involved in regulating diverse cellular functions such as signal transduction, DNA repair, and protein trafficking. FBXL6’s ability to induce K63-linked ubiquitination of ENO1 provides a unique mechanism of protein stabilization, preventing its breakdown and sustaining the metabolic and signaling pathways that promote tumor progression.

ENO1, short for alpha-enolase, is a glycolytic enzyme with well-documented moonlighting functions beyond its metabolic role. Elevated expression of ENO1 has been correlated with increased tumor invasiveness, metastasis, and poor prognosis across several cancer types. However, the precise regulatory mechanisms controlling its stability have remained elusive until now. The stabilization of ENO1 by FBXL6 via K63-linked ubiquitination marks a critical turning point in decoding the molecular circuitry of bladder cancer, offering a novel target for intervention.

The research team employed an array of sophisticated molecular biology techniques, including co-immunoprecipitation assays and ubiquitination analyses, to unravel the interaction between FBXL6 and ENO1. They demonstrated that FBXL6 directly binds to ENO1, catalyzing its modification through K63-linked ubiquitin chains. This process shields ENO1 from proteasomal degradation, effectively increasing its half-life within bladder cancer cells, which in turn fuels oncogenic signaling pathways that drive aggressive tumor growth.

Functional assays revealed that silencing FBXL6 expression in bladder cancer cells resulted in a dramatic decrease in ENO1 levels, accompanied by significant attenuation of cancer cell proliferation, migration, and invasion. These findings underscore the causative role of FBXL6-mediated ENO1 stabilization in promoting malignant phenotypes and highlight its potential as a biomarker for disease progression. The loss of FBXL6 compromised tumor growth in vivo, reinforcing its significance as a therapeutic target.

Moreover, the study illuminated the downstream effects of ENO1 stabilization on key signaling cascades related to cellular metabolism and survival. ENO1 serves as a nexus point for metabolic reprogramming, a hallmark of cancer cells that shift their energy production strategies to support rapid proliferation. By sustaining ENO1 activity, FBXL6 indirectly amplifies glycolytic flux, enhances ATP generation, and facilitates biosynthetic processes essential for tumor maintenance, shedding light on the metabolic vulnerabilities that could be exploited pharmacologically.

Another intriguing aspect of this research is the implication that targeting the ubiquitination machinery itself may offer novel therapeutic strategies. Unlike traditional approaches that focus solely on enzyme inhibition, disrupting the ubiquitination process that protects oncogenic proteins like ENO1 may provide a more effective means of destabilizing tumor-promoting factors. This innovative angle could lead to the development of drugs that selectively interfere with F-box protein functions or modulate ubiquitin signaling pathways in cancer cells.

In light of these findings, the authors propose that inhibitors designed to block the ubiquitin ligase activity of FBXL6 or prevent K63-linked ubiquitination of ENO1 could suppress bladder cancer progression with minimal impact on normal tissues. Such targeted interventions may enhance the efficacy of existing treatments or serve as standalone therapies, addressing the urgent need for precision medicine in bladder cancer management.

The study also prompts further exploration into the broader roles of F-box proteins and ubiquitination patterns in oncogenesis. FBXL6’s selective stabilization of ENO1 through K63-linked ubiquitination exemplifies the diverse regulatory roles ubiquitin chains can fulfill beyond protein degradation, inviting researchers to re-examine this post-translational modification as a multifaceted modulator of cancer biology.

Furthermore, the integration of these molecular insights with clinical data could refine patient stratification and prognostication. Measuring FBXL6 and ENO1 expression levels in tumor samples may help identify high-risk individuals who could benefit from therapies targeting this axis. This precision approach embodies the future of oncology, where molecular characterization guides individualized treatment decisions for better outcomes.

Beyond its immediate implications for bladder cancer, this discovery holds promise for understanding other malignancies where ENO1 overexpression and dysregulated ubiquitination occur. The universality of these molecular players suggests that the FBXL6-ENO1 pathway could constitute a common axis exploited by diverse tumor types, broadening the impact of this research across oncology disciplines.

Importantly, the identification of K63-linked ubiquitination as a stabilizing mechanism challenges the traditional dogma of ubiquitin’s function exclusively as a degradation signal. This nuanced understanding enriches our grasp of cellular homeostasis and malignancy, fostering avenues for innovative research in cancer metabolism, signal transduction, and protein homeostasis.

In conclusion, this pioneering study not only elucidates a novel molecular interaction central to bladder cancer progression but also exemplifies the power of unraveling intricate post-translational modifications to uncover new therapeutic targets. The FBXL6-mediated stabilization of ENO1 via K63-linked ubiquitination represents a compelling mechanistic insight with significant clinical potential. It marks a vital step forward in cancer research, offering hope for improved management strategies in a disease that continues to pose formidable challenges to patients and clinicians alike.

Subject of Research: Bladder cancer progression mechanisms focusing on FBXL6-mediated stabilization of ENO1 via K63-linked ubiquitination

Article Title: FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination

Article References: Huang, R., Yu, J., Bai, R. et al. FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03130-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03130-x

The study conducted by Zhang et al. introduced groundbreaking findings that suggest the knockdown of CCDC137 results in the suppression of bladder cancer development. The meticulous analysis conducted by the research team highlights the potential of this genetic factor as a therapeutic target. By modifying the expression levels of CCDC137, researchers noted a consequential decrease in tumor growth rates, underscoring its critical role in the cellular pathways that fuel the disease’s progression.

Prior studies have often emphasized the complexity of cancer biology, demonstrating that various genes and their products interact in multifaceted ways to regulate cellular behavior. CCDC137’s involvement in these processes represents a novel insight, particularly in how it intersects with fatty acid metabolism through the modulation of stearoyl-CoA desaturase (SCD). This connection is significant, as SCD has previously been implicated in various cancers and is recognized for its role in promoting lipogenesis, which is essential for cellular proliferation and growth.

Understanding the interplay between CCDC137 and SCD opens new doors for therapeutic intervention. By downregulating SCD through the suppression of CCDC137, researchers discovered a notable reduction in key markers associated with bladder cancer survival and invasiveness. This correlation indicates that the manipulation of these biomolecular pathways could prove beneficial in the therapeutic landscape, especially for patients battling advanced forms of the disease.

Further investigations into the specific molecular mechanisms that underpin the interactions between CCDC137 and SCD will be vital for the broader application of these findings. The research emphasizes a need for additional studies to unravel the precise pathways that may be influenced by the knockdown of CCDC137. Understanding these pathways will not only elucidate the role of CCDC137 in bladder cancer but also potentially in other malignancies that share similar metabolic dysregulations.

In addition to elucidating the functions of CCDC137 and SCD, the study also sheds light on the inflammatory microenvironment often associated with tumor development. The researchers speculate that CCDC137 may play a role in modulating inflammatory signaling pathways, which in turn could influence tumorigenesis. This perspective aligns with ongoing research trends that explore the relationship between chronic inflammation and cancer, further reinforcing the complexity of tumor biology.

The implications of these findings extend beyond bladder cancer, suggesting that the mechanisms by which CCDC137 influences cellular metabolism may be relevant to a wider array of cancers. As researchers delve deeper, there is potential for identifying biomarkers that could predict tumor aggressiveness or responsiveness to various therapeutic strategies. Such advancements would be invaluable in personalizing treatment approaches and enhancing patient care.

The ongoing quest for more effective treatments for bladder cancer has reached a pivotal point with these findings. The integration of genetic research into clinical practice presents a promising frontier for oncologists and researchers alike. By focusing on the molecular underpinnings of cancer progression, the medical community stands poised to make informed decisions regarding patient management, ultimately leading to improved survival rates and quality of life.

Moreover, this exploration into genetic knockdown strategies foreshadows a paradigm shift in how cancers are treated. Specifically, the concept of targeting genetic components like CCDC137 provides a fresh blueprint for future drug development. Establishing robust clinical trials to test therapeutic agents that modulate CCDC137 expression could be the next step in capitalizing on the insights provided by Zhang et al.’s study.

As the research community continues to scrutinize the linkage between genetic factors and cancer biology, the potential for discovering novel therapeutic targets is both exciting and hopeful. Coupled with advancements in personalized medicine, this work enriches our understanding of how to combat malignancies at their core rather than merely managing symptoms. The possibility of developing targeted therapies that enhance the body’s natural defenses against tumors cannot be overstated.

In conclusion, the groundbreaking study led by Zhang and colleagues marks a significant leap forward in the field of cancer research. Through their detailed examination of CCDC137 and its effects on SCD and bladder cancer progression, they have unearthed new perspectives that could pave the way for innovative therapeutic interventions. As researchers build upon these findings, the broader implications for cancer treatment are bound to inspire the direction of future studies and clinical applications. The quest for effective bladder cancer therapies is ongoing, but with each advancement, there is renewed hope for improved outcomes for patients affected by this challenging disease.

Subject of Research: The role of CCDC137 in bladder cancer progression and its relationship with stearoyl-CoA desaturase (SCD).

Article Title: CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.

Article References: Zhang, H., Huang, W., Cai, Z. et al. CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD. J Transl Med 23, 1013 (2025). https://doi.org/10.1186/s12967-025-07033-w

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07033-w

Keywords: CCDC137, bladder cancer, SCD, tumor progression, genetic knockdown, molecular biology, cancer therapy, personalized medicine.

Menin has long been a subject of intense scrutiny due to its diverse functions in various cancers such as leukemia, breast, prostate, and liver cancers. Despite extensive investigations, its implication in bladder cancer was previously obscure. The new study, conducted collaboratively by leading researchers across several prominent institutions including Harbin Medical University and Shanghai Jiaotong University School of Medicine, sheds light on this gap by demonstrating menin’s oncogenic properties in BLCA.

Initial analyses involving mRNA and protein expression profiles of bladder cancer patient tissues revealed that MEN1 is significantly upregulated in tumor samples compared to healthy controls. These elevated levels correlate closely with clinical parameters indicative of aggressive disease – notably advanced tumor stage, presence of lymph node metastasis, and increased patient age. Moreover, high MEN1 expression portends poor overall survival, underlining its clinical relevance as a potential prognostic biomarker.

Functional studies employing RNA interference to knock down MEN1 expression in bladder cancer cell lines yielded compelling evidence of menin’s role in tumorigenesis. MEN1 depletion led to marked inhibition of cell proliferation and induced a pronounced G1/S phase arrest in the cell cycle, signifying that menin facilitates cell cycle progression and cell division in BLCA cells. Supporting this, xenograft experiments in nude mice demonstrated a significant reduction in tumor volume upon MEN1 silencing, confirming menin’s tumor-promoting capacity in vivo.

To elucidate the molecular mechanisms underpinning menin’s oncogenic activity, the research team performed RNA sequencing coupled with KEGG pathway enrichment analysis. The results revealed that MEN1 knockdown induces profound alterations in gene expression across multiple biological pathways, including key regulators of the Wnt signaling cascade, autophagy, mitophagy, nucleotide excision repair, and apoptosis. These widespread transcriptional changes emphasize menin’s integral role in orchestrating diverse cellular processes central to cancer cell survival and proliferation.

Strikingly, the study found that menin modulates the Wnt/β-catenin signaling pathway, a canonical pathway often dysregulated in cancer. MEN1 knockdown significantly reduced β-catenin (encoded by CTNNB1) expression at both the mRNA and protein levels. Mechanistic assays revealed that menin directly binds to the proximal promoter region of CTNNB1, thereby activating its transcription and sustaining β-catenin signaling within BLCA cells. This novel insight into menin’s regulatory control over β-catenin highlights a critical axis driving bladder tumorigenesis.

Delving deeper, the researchers identified another transcription factor, TFAP2C, as a direct target of menin. Menin binds to the proximal promoter of TFAP2C in a manner mediated by the Mixed Lineage Leukemia (MLL) complex, leading to upregulation of TFAP2C expression. Intriguingly, subsequent experiments demonstrated that TFAP2C itself binds to the CTNNB1 promoter and is indispensable for the menin-dependent activation of the Wnt/β-catenin pathway. The data collectively articulate a sophisticated regulatory cascade whereby menin enhances TFAP2C expression, which in turn drives β-catenin transcription, reinforcing malignant cell proliferation.

This comprehensive characterization of the menin/TFAP2C/β-catenin signaling axis underscores a potential therapeutic vulnerability in bladder cancer. In light of this, the study evaluated BAY-15522, a small molecule inhibitor specifically targeting menin. Treatment with BAY-15522 effectively suppressed the proliferation of BLCA cells and curtailed tumor growth in preclinical models by disrupting the menin-mediated signaling network. These findings not only confirm menin’s oncogenic role but also position menin inhibitors as promising candidates for clinical intervention in BLCA management.

The implications of this research extend beyond bladder cancer, offering a conceptual framework for targeting menin and its downstream pathways in other malignancies where menin is aberrantly expressed. The ability of menin to regulate transcription factors and oncogenic signaling pathways highlights its multifunctional role as a master regulator of cancer cell biology. Therapeutically, targeting such central nodes could yield more durable and widespread anti-cancer effects.

Moreover, the observed positive correlation between MEN1 expression and tumor stage, patient age, and lymph node involvement suggests that menin could serve as a useful prognostic marker to stratify patient risk and personalize treatment approaches. Measuring MEN1 levels in clinical settings might help identify individuals who would benefit most from menin-targeted therapies, aligning with precision medicine goals.

This study also paves the way for future research to explore the broader interactome of menin in bladder cancer cells, investigating other potential co-factors and signaling pathways that may contribute to tumor progression and resistance mechanisms. The integration of epigenetic regulators, DNA repair machineries, and apoptosis pathways within menin’s influence opens many avenues for combinatorial therapeutic strategies.

In summary, this transformative research provides compelling evidence that menin acts as a critical oncogene in bladder cancer by orchestrating a regulatory axis involving TFAP2C and β-catenin, thus enhancing cell proliferation and tumor growth. Pharmacological inhibition of this axis impairs BLCA progression, spotlighting menin as an attractive molecular target for innovative therapeutics. As bladder cancer continues to pose clinical challenges worldwide, these insights offer renewed hope for developing more effective and targeted treatment modalities.

Subject of Research: The oncogenic role of menin (MEN1 gene product) in bladder cancer progression and its underlying molecular mechanisms.

Article Title: Menin facilitates the cell proliferation of bladder cancer via modulating the TFAP2C/β-catenin axis

Web References:

• GSEA software: https://www.gsea-msigdb.org/gsea/index.jsp
• Genes & Diseases Journal on ScienceDirect: https://www.sciencedirect.com/journal/genes-and-diseases
• DOI Link: http://dx.doi.org/10.1016/j.gendis.2025.101565

References:
Shi Q., Pan X., Zhang S., Wu M., Xu M., Li Y-Q., Zhong L., Wang Z-Q., Xu W., Luo Y. (2025). Menin facilitates the cell proliferation of bladder cancer via modulating the TFAP2C/β-catenin axis. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101565.

Image Credits: Qing Shi, Xiang Pan, Shiheng Zhang, Mengyuan Wu, Meiqi Xu, Yun-Qi Li, Li Zhong, Zi-Qi Wang, Wanhai Xu, Yakun Luo

Keywords: Cell proliferation, Cancer, Bladder cancer, MEN1, Menin, TFAP2C, β-catenin, Wnt signaling, Cell cycle, RNA interference, Xenograft model, Molecular oncology

Traditionally, bladder cancer has been viewed through a lens that often overlooks the biological and physiological distinctions between the sexes. The implications of these distinctions are profound and are starting to be understood at a deeper level. Men are diagnosed with bladder cancer more than three times as often as women, yet the reasons behind this disparity have remained somewhat enigmatic. This research indicates that hormonal differences, genetic factors, and environmental exposures contribute significantly to this variance.

The role of hormones in bladder cancer is particularly intriguing. Testosterone and estrogen, which play crucial roles in the pathophysiology of various cancers, seem to exert opposing effects in bladder tissue. The study suggests that higher levels of estrogen in females might afford some protective effect against the development of bladder tumors, potentially inhibiting tumor growth and providing insight into why men are diagnosed more frequently. Conversely, the interplay of androgens and the prevalence of smoking in males could exacerbate their risk.

Furthermore, the genetics of bladder cancer also appear to diverge by sex. The incidence of certain mutations and the expression of specific genes vary between male and female patients. The research indicates that variations in the tumor microenvironment could influence tumor behavior differently based on sex. These findings emphasize that treatment strategies must consider these genetic factors. For instance, the response to common chemotherapy drugs such as cisplatin may be gender-dependent, necessitating individualized treatment approaches that take sexual dimorphism into account.

Environmental factors are another essential aspect of this research. Lifestyle choices, particularly smoking and exposure to carcinogens, are more prevalent among men, contributing to their higher rates of bladder cancer. The research delves into the epidemiology of bladder cancer, discussing how factors such as occupation, exposure to specific chemicals, and even diet can influence cancer rates by sex. Women often have lower exposure rates and different susceptibility to carcinogenic agents, which could explain some of the observed disparities.

Notably, the study reveals that not all bladder cancer subtypes behave similarly in men and women. For instance, muscle-invasive bladder cancer, which often has a poorer prognosis, shows different biological markers in male patients compared to female patients. By identifying these differences, researchers hope to develop tailored treatments that can effectively target the specific subtypes of bladder cancer that are more prevalent in one sex or the other.

Another critical angle explored in the research is the impact of late diagnosis and subsequent treatment outcomes, which often differ by sex as well. Women are often diagnosed at a later stage of the disease, possibly due to misattributions of their symptoms to urinary tract infections or other benign conditions more common among females. This delayed diagnosis can lead to poorer prognosis and highlights the need for better awareness and education regarding the signs and symptoms of bladder cancer in women.

The psychological aspects of coping with a bladder cancer diagnosis also reveal interesting differences between the sexes. Men and women may respond differently to the emotional burden of a cancer diagnosis, influencing their treatment choices and adherence to recommendations made by healthcare providers. Understanding these psychological differences can facilitate the development of more effective support systems tailored to the unique needs of each sex.

Importantly, this research does not only seek to delineate the problem but also paves the way for significant advancements in how we approach bladder cancer. Insight into sex-based biological differences will enable oncologists and researchers to innovate new therapies that could improve outcomes for both men and women. Such advancements could include precision medicine approaches that utilize genetic profiling to determine the most effective treatments based on an individual’s sex and genetic makeup.

As we drive toward more personalized medicine, the implications of these findings reach beyond bladder cancer. Other cancers may also exhibit sex-based disparities, suggesting a broader need for research that acknowledges and investigates these crucial differences. Armed with this knowledge, the medical community can better address cancer as a multifaceted disease that requires a comprehensive understanding of the patient’s biology, environment, and psychological state.

In conclusion, the study by Chaudhary, Singha, and Abdel-Hafiz marks a significant step forward in our understanding of bladder cancer through the lens of sex differences. These findings are not merely academic; they are vital in transforming clinical practices and improving survival rates. The evolution of treatment paradigms that take into account the unique biological and psychological dimensions of each sex will undoubtedly lead to improved health outcomes and a better quality of life for bladder cancer patients across the board. With ongoing research and a commitment to understanding these differences, we can usher in a new era of personalized cancer care, offering hope to those affected by this challenging disease.

Subject of Research: Bladder Cancer and Sex Differences

Article Title: Understanding Biological and Clinical Implications of Sex Differences in Bladder Cancer

Article References:

Chaudhary, P., Singha, B., Abdel-Hafiz, H.A. et al. Sex differences in bladder cancer: understanding biological and clinical implications.
Biol Sex Differ 16, 31 (2025). https://doi.org/10.1186/s13293-025-00715-6

Image Credits: AI Generated

DOI: 10.1186/s13293-025-00715-6

Keywords: Bladder cancer, sex differences, hormonal factors, genetic variations, environmental exposures, personalized medicine.